MÉRIEUX-EQUITY
18.2.2021 08:02:12 CET | Business Wire | Press release
AcuSurgical, a Montpellier-based company focused on robotic microsurgery, today announces a €5.75 million Series A financing round led by Mérieux Equity Partners (via OMX Europe Venture Fund) and Supernova Invest (via Supernova 2 Fund), with Sofimac Innovation (via Pertinence Invest 2 Fund) and IRDI Capital Investissement (via Irdinov 2 and Inn’Vest PME Occitanie Est Funds) participating in the round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005035/en/
Using advanced robotics, AcuSurgical is making ocular microsurgery safer and more accessible by dramatically improving the precision of surgical interventions. A proof of concept of the platform has already been completed with a first prototype validated in a preclinical setting.
The company will use the proceeds of the Series A financing to conduct clinical trials and reach regulatory approval with vitreo-retinal surgery as the first indication, paving the way for future applications that are not within the reach of surgeons today.
Retinal surgeries represent an annual global market of 1.6 million procedures, currently performed by a limited number of specialized surgeons. AcuSurgical’s robotic platform aims to increase the precision of current procedures, filtering tremor and augmenting visualization with the aid of a telemanipulated robot, while the surgeon remains in complete control.
Founded by Christoph Spuhler, serving as Chief Executive Officer, AcuSurgical has already attracted an experienced and highly skilled multidisciplinary team of executives, alongside the scientific co-founders, Prof. Yassine Haddab and Prof. Philippe Poignet, robotics experts at the joint research Unit LIRMM (Laboratory of Computer Science, Robotics and Microelectronics in Montpellier) and Prof. Philippe Gain and Prof. Gilles Thuret, retinal surgeons at the Saint-Etienne University Hospital.
“Our ambition is to enable new treatments for retinal disease that will open new perspectives for the numerous patients who are impacted by these debilitating retinal conditions. We are proud of the vote of confidence by this strong syndicate of investors. This financing will allow us to grow the team and reach key milestones towards certification and commercialisation of a truly innovative surgical solution”, s ays Christoph Spuhler, CEO and co-founder of AcuSurgical.
“We are delighted to partner with such an experienced team and look forward to supporting AcuSurgical in bringing to market a novel solution that will improve ocular surgeries and open new procedures in ophthalmology” , says Valérie Calenda, Managing Partner at Mérieux Equity Partners.
”The robotics platform developed by AcuSurgical aims to help retinal surgeons perform complex procedures more safely and reproducibly. We are very pleased to support this new venture and excellent team” says Celia Hart, General Partner at Supernova Invest.
About AcuSurgical - www.acusurgical.com
Founded in 2020, AcuSurgical is a surgical robotics company based in Montpellier (France). AcuSurgical's mission is to enable top-class treatment to the 300+ million patients suffering from retinal disease worldwide, a debilitating condition including age-related macular degeneration (AMD), diabetic retinopathy and macular holes. Worldwide, currently 1.6 million retinal surgeries are performed each year, with a yearly growth rate of 7%. This currently represents only a small percentage of actual cases, with the majority of patients, especially in emerging economies, getting inadequate treatment or often no treatment at all. The cutting-edge robotics platform from AcuSurgical aims to change this, bringing a new surgical paradigm to vitreo-retinal surgery based on precision robotics.
About Mérieux Equity Partners - www.merieux-partners.com
Mérieux Equity Partners (“MxEP”) is an investment company dedicated to capital investment in health and nutrition and registered with the Autorité des Marchés Financiers (AMF). MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages around €670 million of assets and launched their latest venture capital fund in 2020, OMX Venture Fund, to finance high potential companies in the life science space, in Europe and North America.
About Supernova Invest - www.supernovainvest.com
Supernova Invest is a cutting-edge venture capital firm with a leading position in the French deeptech investment market. It manages and advises five capital funds for a total of €260 million AUM. Supernova Invest specializes in breakthrough technologies, developing start-ups in Industry, Health, Energy & Environment and Digital Technology sectors. Supernova Invest has a strong partnership with both the CEA (the French Alternative Energies and Atomic Energy Commission) and Amundi (the European leader in asset management).
The FPCI Supernova 2 is an early-stage investment fund managed by Supernova Invest. Its main investors are the Crédit Agricole, the Fond National d’Amorçage managed by Bpi France, the CEA, Michelin, BioMérieux, Vinci, EDF, CGG, UDIMEC as well as entrepreneurs and family offices.
About Sofimac Innovation - www.sofimacinnovation.com
Sofimac Innovation is an independent management company certified by the financial markets regulator (AMF) and dedicated to technological and innovative investment. Based in Paris, Lyon, Rennes and Marseille, Sofimac Innovation supports innovative start-up in their growth projects with a wide range of investment vehicles. Working in a wide variety of technological sectors, particularly in Health and Digital sectors, Sofimac Innovation is currently managing 9 Funds comprising around 90 active companies.
Pertinence Invest 2 is an investment Fund managed by Sofimac Innovation, raised in partnership with prestigious Universities and Schools and renowned industrial corporates. Pertinence Invest 2 is investing in breakthrough technologies in the Engineering Sciences and Health & Nutrition sectors.
About IRDI Capital Investissement - www.irdi.fr
Based in Toulouse, Montpellier, and Bordeaux, IRDI Capital Investissement has been a key player in private equity for more than 35 years, with an investment track record in companies located in the South-West of France and at all development stages. It manages more than €350 million spread across several funds, including IRDINOV 2 and INN’VEST PME OCCITANIE EST which were both leveraged to invest in AcuSurgical.
IRDINOV 2 - supported by the Fonds National d’Amorçage (FNA) - is a capital seed fund specialized in financing technological companies.
INN’VEST PME OCCITANIE EST is a co-investment fund supported by the European Investment Fund (EIF) and the Région Occitanie under the FOSTER TPE PME fund of funds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom